Title |
Plasma trimethylamine-N-oxide and related metabolites are associated with type 2 diabetes risk in the Prevención con Dieta Mediterránea (PREDIMED) trial
|
---|---|
Published in |
American Journal of Clinical Nutrition, July 2018
|
DOI | 10.1093/ajcn/nqy058 |
Pubmed ID | |
Authors |
Christopher Papandreou, Mònica Bulló, Yan Zheng, Miguel Ruiz-Canela, Edward Yu, Marta Guasch-Ferré, Estefanía Toledo, Clary Clish, Dolores Corella, Ramon Estruch, Emilio Ros, Montserrat Fitó, Fernando Arós, Miquel Fiol, José Lapetra, Lluís Serra-Majem, Enrique Gómez-Gracia, Liming Liang, Georgios A Fragkiadakis, Cristina Razquin, Frank B Hu, Jordi Salas-Salvadó |
Abstract |
The role of trimethylamine-N-oxide (TMAO) in type 2 diabetes (T2D) is currently partially understood and controversial. The aim of this study was to investigate associations between TMAO and related metabolites with T2D risk in subjects at high risk of cardiovascular disease. This is a case-cohort design study within the Prevención con Dieta Mediterránea (PREDIMED) study, with 251 incident T2D cases and a random sample of 694 participants (641 noncases and 53 overlapping cases) without T2D at baseline (median follow-up: 3.8 y). We used liquid chromatography-tandem mass spectrometry to measure plasma TMAO, l-carnitine, betaine, lyso-phosphatidylcholine (LPC) and lyso-phosphatidylethanolamine (LPE) species, phosphocholine, α-glycerophosphocholine, and choline at baseline and after 1 y. We examined associations with the use of weighted Cox proportional hazard models, accounting for the weighted case-cohort design by the Barlow method. After adjustment for recognized T2D risk factors and multiple testing, individuals in the highest quartile of baseline TMAO and α-glycerophosphocholine had a lower risk of T2D [HR (95% CI): 0.52 (0.29, 0.89) and 0.46 (0.24, 0.89), respectively]. The HR (95% CI) comparing the extreme quartiles of betaine was 0.41 (0.23, 0.74). Similar trends were observed for C16:0 LPC, C18:1 LPC, C18:0 LPC, C20:4 LPC, C22:6 LPC, C18:1 LPC plasmalogen, and C16:0 LPE. After correcting for multiple comparisons, participants in the highest quartile of 1-y changes in oleic acid LPC plasmalogen concentrations had a lower T2D risk than the reference quartile. Whether the associations between plasma TMAO and certain metabolite concentrations with T2D risk reflect its pathophysiology or represent an epiphenomenon needs to be elucidated. This trial is registered at http://www.controlled-trials.com as ISRCTN35739639. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 4 | 44% |
Belgium | 1 | 11% |
Unknown | 4 | 44% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 5 | 56% |
Scientists | 2 | 22% |
Science communicators (journalists, bloggers, editors) | 1 | 11% |
Practitioners (doctors, other healthcare professionals) | 1 | 11% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 83 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 12 | 14% |
Student > Bachelor | 9 | 11% |
Researcher | 7 | 8% |
Student > Master | 6 | 7% |
Student > Doctoral Student | 5 | 6% |
Other | 17 | 20% |
Unknown | 27 | 33% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 20 | 24% |
Biochemistry, Genetics and Molecular Biology | 7 | 8% |
Nursing and Health Professions | 6 | 7% |
Engineering | 3 | 4% |
Agricultural and Biological Sciences | 2 | 2% |
Other | 8 | 10% |
Unknown | 37 | 45% |